Type 2 diabetes (T2D) is the most common form of ... even though glycemic control was the focus of the 2017 guidelines of the American College of Physicians (ACP). Therefore, the ACP deemed ...

Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with prediabetes and obesity or overweight, according to 3-year results from the SURMOUNT-1 trial.

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

In SURMOUNT-1, adults with prediabetes receiving tirzepatide were 94% less likely to develop type 2 diabetes than placebo at 176 weeks. Those receiving 15 mg tirzepatide lost 22.9% of their body ...

Those with CKD receiving tirzepatide had larger urine albumin-to-creatinine ratio reductions. Perspective from M. Luiza Caramori, MD, MSc, PhD Adults with type 2 diabetes receiving tirzepatide had ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared ...

Morningstar brands and products Company Portfolio ...

"Some of the mechanisms through which semaglutide and tirzepatide lower blood sugar in type 2 diabetes are also likely to be relevant in type 1 diabetes," says study leader Dr. Janet Snell-Bergeon ...

More information: Min-Hsiang Chuang et al, Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes, JAMA Network Open (2024). DOI: 10.1001/jamanetworkopen ...

Drug manufacturer Eli Lilly announced the results from a three-year study that found its drug tirzepatide slashed the risk of developing type 2 diabetes by 94% in adults with prediabetes who also ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...